Last €109.56 EUR
Change Today -0.05 / -0.05%
Volume 378.4K
FRE On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
Xetra
As of 3:45 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

fresenius se & co kgaa (FRE) Snapshot

Open
€110.17
Previous Close
€109.61
Day High
€110.35
Day Low
€108.35
52 Week High
02/17/14 - €120.60
52 Week Low
09/10/13 - €87.00
Market Cap
19.7B
Average Volume 10 Days
339.4K
EPS TTM
€5.81
Shares Outstanding
180.0M
EX-Date
05/19/14
P/E TM
18.9x
Dividend
€1.25
Dividend Yield
1.14%
Current Stock Chart for FRESENIUS SE & CO KGAA (FRE)

Related News

No related news articles were found.

fresenius se & co kgaa (FRE) Related Businessweek News

No Related Businessweek News Found

fresenius se & co kgaa (FRE) Details

Fresenius SE & Co. KGaA provides products and services for dialysis, hospital, and outpatient medical care worldwide. Its Fresenius Medical Care segment provides products for hemodialysis and peritoneal dialysis; and dialysis care services at its clinics. This segment also offers dialyzers, dialysis machines, and renal pharmaceuticals; and performs clinical laboratory tests. As of December 31, 2013, it treated patients with approximately 3,250 dialysis clinics. The company's Fresenius Kabi segment offers therapy and care products for chronically and critically ill patients. This segment provides intravenously administered generic drugs, such as anesthetics, anti-infectives, and analgesics, as well as drugs for the treatment of oncological and other critical diseases; infusion solutions and blood volume replacement products for infusion therapy; parenteral and enteral nutrition products; infusion and nutrition pumps; and transfusion technology comprising products that are used in the collection and processing whole blood and blood components, as well as in transfusion medicine. Its Fresenius Helios segment operates approximately 74 hospitals, including 51 acute care hospitals and 23 post acute care clinics; 35 outpatient facilities; and 13 nursing homes with approximately 23,000 beds. The company's Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers planning and construction services for turnkey construction projects, and medical-technical and building utilities, as well as executes projects as general contractor; and provides technical facility and operational management services, as well as replacement parts sourcing services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg, Germany.

201,924 Employees
Last Reported Date: 05/9/14
Founded in 1912

fresenius se & co kgaa (FRE) Top Compensated Officers

Chairman of the Management Board - Fresenius ...
Total Annual Compensation: €2.4M
Chief Financial Officer of Fresenius Manageme...
Total Annual Compensation: €1.5M
Chief Executive Officer of Fresenius Kabi
Total Annual Compensation: --
Chief Legal & Compliance Officer of Fresenius...
Total Annual Compensation: €1.1M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €1.5M
Compensation as of Fiscal Year 2013.

fresenius se & co kgaa (FRE) Key Developments

Fresenius SE & Co. KGaA Approves Dividend

Fresenius SE & Co. KGaA announced that the Annual General Meeting of shareholders of the company was held on May 20, 2014, has approved the 21st consecutive dividend increase proposed by the general partner and the Supervisory Board. The dividend was raised by 14% to EUR 1.25 per share (2012: EUR 1.10 per share). This increase is in line with the growth in earnings per share before special items, in accordance with the new dividend policy introduced last year.

Fresenius Reaffirms Its Earnings Guidance for the Fiscal Year 2014; Provides Earnings Guidance for the Fiscal Year 2017

Fresenius reaffirmed its earnings guidance for the fiscal year 2014. For the year, the company plans to increase sales by 12% to 15%, and net income by 2% to 5% before special items, both of these at constant currency. For the fiscal year 2017, the company target sales of about EUR 30 billion, and net income of EUR 1.4 billion to EUR 1.5 billion. This represents increases of approximately half, in both sales and net income, within just four years.

Fresenius Announces Earnings Results for the First Quarter of Fiscal 2014

Fresenius announced earnings results for the first quarter of fiscal 2014. For the quarter, the company announced sales came in at just above EUR 5.2 billion, that is 11% growth at constant currency. EBIT reached EUR 643 million and that's down 8% at constant currency. Net income came in at EUR 228 million, up 2% reported and up 3% at constant currency.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRE:GR €109.56 EUR -0.05

FRE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $76.87 USD +0.76
CareFusion Corp $44.32 USD -0.16
Draegerwerk AG & Co KGaA €60.26 EUR -1.12
Fresenius Medical Care AG & Co KGaA €49.82 EUR +0.035
Hospira Inc $50.78 USD +0.31
View Industry Companies
 

Industry Analysis

FRE

Industry Average

Valuation FRE Industry Range
Price/Earnings 19.1x
Price/Sales 0.9x
Price/Book 2.3x
Price/Cash Flow 19.1x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS SE & CO KGAA, please visit www.fresenius.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.